Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model

(2017) Kevin J. Freise et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

(2017) John F Seymour et al.   LANCET ONCOLOGY

Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma

(2017) Apurvasena Parikh et al.   LEUKEMIA & LYMPHOMA

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

(2016) Aksana K. Jones et al.   AAPS Journal

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

(2016) D. de Wit et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis

(2016) Kevin J. Freise et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers

(2016) Ahmed Hamed Salem et al.   CLINICAL DRUG INVESTIGATION

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

(2016) Kevin J. Freise et al.   CLINICAL PHARMACOKINETICS

Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites

(2016) Hong Liu et al.   DRUG METABOLISM AND DISPOSITION

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy

(2016) Kevin J. Freise et al.   HEMATOLOGICAL ONCOLOGY

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study

(2016) Suresh K. Agarwal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

P-glycoprotein and its role in drug-drug interactions

(2016) Andrew Finch et al.   Australian Prescriber

Suitability of digoxin as a P-glycoprotein probe: Implications of other transporters on sensitivity and specificity

(2013) Ahmed M. Nader et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The P-Glycoprotein Transport System and Cardiovascular Drugs

(2013) Jeffrey D. Wessler et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin

(2012) Xavier Delavenne et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Digoxin Is Not a Substrate for Organic Anion-Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but Is a Substrate for a Sodium-Dependent Transporter Expressed in HEK293 Cells

(2011) M. E. Taub et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin

(2011) Joachim Stangier et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Gauging the clinical significance of P‐glycoprotein‐mediated herb‐drug interactions: Comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics

(2008) Bill J. Gurley et al.   MOLECULAR NUTRITION & FOOD RESEARCH